A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA

Inclusion criteria

• Severe aplastic anemia;
• Aged 40-60 years old;
• Weight 45Kg-100Kg;
• Eastern Cooperative Oncology Group (ECOG) score ≤3;
• No major organ injury (ECG ejection fraction >45%; bilirubin < 2 times the upper limit of normal value; AST and ALT < 3 times the upper limit of normal value; serum creatinine < 2 times the upper limit of normal value);
• No severe infection;
• Subjects voluntarily participated in this clinical trial and signed the informed consent.

Exclusion criteria

• With other hematologic diseases;
• Expected survival of less than 1 month;
• Previous autologous or allogeneic hematopoietic stem cell transplantation;
• Pregnant patients;
• Patients with severe mental or neurological disorders that would affect the ability to provide informed consent and/or to report or observe adverse events;
• Other conditions that the investigator determines to be inappropriate for enrollment.
• Current or recent (<4 weeks prior to screening) clinically serious viral, bacterial, fungal, or parasitic infection
• A history of symptomatic herpes zoster infection within 12 weeks prior to screening
• Active or chronic viral infection from hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
• Have evidence of active tuberculosis (TB), or have previously had evidence of active TB and did not receive appropriate and documented treatment, or have had household contact with a person with active TB and did not receive appropriate and documented prophylaxis for TB
• Exposure to a live vaccine within 12 weeks prior to enrollment or expected to receive a live vaccine during the study
• Clinically significant thrombotic event within 24 weeks of screening or are on anticoagulants and in the opinion of the investigator are not well controlled
• Myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage IV heart failure
• A history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data
• Any of the following specific abnormalities on screening laboratory tests:

• ALT or AST >2 x ULN, or total bilirubin ≥1.5 x ULN
• hemoglobin <9 g/dL, or total white blood cell (WBC) count <2,500/µL, or neutropenia (absolute neutrophil count <1,200/µL), or lymphopenia (lymphocyte count <750/µL)
• eGFR <50 mL/min/1.73 m2